15763 Results

People

  1. Hudis
    Hudis
  2. Offit
    Offit
  3. Zelefsky
    Zelefsky
  4. Giralt
    Giralt
  5. Robson
    Robson
  6. Yahalom
    Yahalom
  7. Wolden
    Wolden
  8. Coit
    Coit
  9. Marghoob
    Marghoob
  10. Tuttle
    Tuttle

Groups

  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)
  7. Division of Subspecialty Medicine (3242)
  8. Center for Hematologic Malignancies (2610)
  9. Biostatistics Service (2488)
  10. GSK Faculty (2413)
  1. "Survivorship Research"
Formats
  1. Journal Article (8900)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15763)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An ongoing phase 1/1b trial investigating novel treatment regimens with mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Kim, W. S.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Budde, L. E.; Cheah, C.; Gregory, G. P.; Hong, J.; Ku, M.; Marlton, P.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Real‐world assessment of practice efficiency with the introduction of subcutaneous rituximab
    Meeting Abstract

    Matasar, M. J.; Qiu, A.; Shapouri, S.; Drill, E. N.; Schade, J.; Ravelo, A.; Ni, A.; To, T. M.; Dawson, K. L.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation impacts on immune evasive mechanisms in relapsed/refractory diffuse large B‐cell lymphoma – A single center experience
    Meeting Abstract

    Sauter, C. S.; Lin, R. J.; Ho, C.; Devlin, S. M.; Maloy, M. A.; Perales, M.; Dahi, P. B.; Schoder, H.; Jakubowski, A. A.; Barker, J. N.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Grade 3A follicular lymphoma can be effectively controlled with very low dose radiation therapy
    Meeting Abstract

    Imber, B. S.; Chau, K.; Goldberg, E.; Joffe, E.; Yahalom, J.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Managing cytokine release syndrome (CRS) and neurotoxicity with step‐up dosing of mosunetuzumab in relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphoma (NHL)
    Meeting Abstract

    Sehn, L. H.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Diefenbach, C. M.; Flinn, I.; Hong, J. Y.; Kim, W. S.; Matasar, M.; Nastoupil, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Highly favorable outcomes with RT followed by ASCT in low/low‐intermediate secondary age adjusted IPI rel/ref DLBCL patients refractory to salvage chemotherapy
    Meeting Abstract

    Yang, J. C.; Chau, K. W.; Scordo, M.; Sauter, C. S.; Yahalom, J.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; DeSelm, C.; Batlevi, C.; Dahi, P. B.; Giralt, S.; Noy, A. M.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save